Teva Pharmaceutical Industries (TEVA) – Analysts’ Recent Ratings Changes

Posted by on May 14th, 2026

Several analysts have recently updated their ratings and price targets for Teva Pharmaceutical Industries (NYSE: TEVA):

  • 5/6/2026 – Teva Pharmaceutical Industries had its price target raised by Barclays PLC from $38.00 to $40.00. They now have an “overweight” rating on the stock.
  • 5/2/2026 – Teva Pharmaceutical Industries was downgraded by Wall Street Zen from “strong-buy” to “hold”.
  • 4/30/2026 – Teva Pharmaceutical Industries had its price target raised by JPMorgan Chase & Co. from $35.00 to $40.00. They now have an “overweight” rating on the stock.
  • 4/30/2026 – Teva Pharmaceutical Industries had its price target raised by UBS Group AG from $36.00 to $42.00. They now have a “buy” rating on the stock.
  • 4/30/2026 – Teva Pharmaceutical Industries had its “overweight” rating reaffirmed by Piper Sandler. They now have a $42.00 price target on the stock, up from $41.00.
  • 4/30/2026 – Teva Pharmaceutical Industries had its price target raised by Truist Financial Corporation from $42.00 to $45.00. They now have a “buy” rating on the stock.
  • 4/20/2026 – Teva Pharmaceutical Industries had its “sell (d-)” rating reaffirmed by Weiss Ratings.
  • 4/9/2026 – Teva Pharmaceutical Industries had its price target raised by Bank of America Corporation from $38.00 to $42.00. They now have a “buy” rating on the stock.

Insider Activity at Teva Pharmaceutical Industries

In other news, insider Brian Savage sold 1,127 shares of the business’s stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $31.67, for a total transaction of $35,692.09. Following the sale, the insider directly owned 10,914 shares in the company, valued at approximately $345,646.38. The trade was a 9.36% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Christine Fox sold 21,258 shares of the business’s stock in a transaction dated Thursday, April 30th. The stock was sold at an average price of $35.31, for a total value of $750,619.98. Following the sale, the executive vice president owned 63,647 shares in the company, valued at approximately $2,247,375.57. This trade represents a 25.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 1,127,018 shares of company stock valued at $37,298,712. Corporate insiders own 0.54% of the company’s stock.

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.

Featured Stories

Receive News & Ratings for Teva Pharmaceutical Industries Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Ltd and related companies with MarketBeat.com's FREE daily email newsletter.